97 results about "Unstable angina" patented technology

The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.

Methods and devices for improved targeting to a site in an organism, particularly to a tumor target site and for extracorporeal affinity adsorption, particularly in the treatment of cancer, atherosclerosis, including coronary artery disease, unstable angina, other acute ischemic syndromes and idiopathic dilated cardiac myopathy. In one aspect of the invention, a combination is provided comprising an extracorporeal device (1) having contained therein a binding compound (11) bound to a carrier (9), the binding compound having affinity for a binding partner, and a plurality of affinity binders (15), each of said affinity binders comprising a first portion (19) comprising the binding partner and a second portion (17) adapted to bind selectively with a species, the second portions of each of said affinity binders differing from each other.

The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use.

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.

Method is provided of treating or preventing hypertrophy, hypertension, myocardial ischemia, ischemic heart disease, myocardial infarction, congestive heart failure, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia reperfusion injury, preventing death subsequent to myocardial infarction, cerebral infarction, contractile dysfunction subsequent to myocardial infarction, or arrhythmia in a mammal with low doses of pyridoxine, pyridoxal-5′phosphate, pyridoxal or pyridoxamine. Compositions and kits for said method is also included.

The present invention relates to the identification of chemokine biomarkers predictive of future acute coronary syndromes including unstable angina pectoris (UAP). The present invention also identifies particular chemokines as potential therapeutic targets for intervention in cardiovascular diseases.

The present invention relates to methods for the diagnosis and evaluation of acute coronary syndromes. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for myocardial injury and one or more non-specific markers for myocardial injury. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. In various aspects, the invention provides methods for the early detection and differentiation of stable angina, unstable angina, and myocardial infarction. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

Methods of determining levels of unbound metabolites are disclosed. Probes derived from fatty acid binding protein muteins are described that bind preferentially to a number of unbound metabolites including oleate, stearate, linoleate, palmitate, arachidonate and unconjugated bilirubin. A profile for a patient is determined using one or more of the described probes. The profile is useful in diagnosis of disease, particularly myocardial infarction, non-alcoholic fatty liver disease (NAFLD), diabetes, stroke, sepsis and neonatal jaundice. The responses of multiple probes to a test sample are used to classify the degree of acute coronary syndrome by comparison to multi-probe profiles generated from unstable angina, non ST elevation myocardial infarction, and ST elevation myocardial infarction.

The invention relates to a method for treatment of unstable coronary artery disease, which is characterised by an early revascularisation together with administration of a low molecular weight heparin. Preferably the low molecular weight heparin is administered up to revascularisation. The methods are also useful for treatment of unstable angina and not worsening chest pain and for treatment of non-Q-wave myocardial infarction (mild heart attack).

The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.

An orally taken enteric Chinese medicine in the form of tablet, capsule, dripping pill, or soft capsule for treating unstable angina pectoris, acute myocardial infarction, cerebral haemorrhage, etc and preventing deep phlebothrombosis is prepared from leech. Its preparing process is also disclosed.

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.

The invention relates to a polypeptide used for prevention and treatment of acute coronary syndrome and anticoagulation antithrombotic therapy and application thereof. A sequence of the polypeptide disclosed by the invention is P1 Pro-Ser-Hyp-Gly-Asp-TrpP2 Pro-Ser-Hyp-Gly-Asp-Trp-ArgP3 Pro-Ser-Lys-Gly-Asp-TrpP4 Pro-Ser-Val-Gly-Asp-TrpP5 Pro-Ser-Nva-Gly-Asp-Trp-ArgP6 Pro-Ser-Pro-Gly-Asp-TrpP7 Pro-Ser-Thz-Gly-Asp-Trp, the polypeptide is independently used or combined with aspirin, clopidogrel or heparin, is used for inhibiting platelet aggregation and thrombosis and is taken as an effective ingredient for preparing a medicine used for prevention and treatment of acute coronary syndrome, unstable angina and acute myocardial infarction and intervention therapy of anticoagulation antithrombotic therapy. The polypeptide provided by the invention can be combined with a human blood platelet GPIIb-IIIa receptor, and has the capabilities of blocking blood platelet aggregation induced by adenosine diphosphate, arachidonic acid and thrombin and effectively inhibiting coronary thrombosis and femoral thrombosis.

The medicine composition has synergistic active components trifusal and clopidogrel, and its clopidogrel exists in free state or pharmaceutically acceptable salt. The medicine composition is used in treating stable or unstable angina pectoris and other cardiac and cerebral vascular diseases. Pharmaceutical experiments prove the synergistic effect of trifusal and clopidogrel in the medicine composition and the medicine composition has blood platelet inhibiting rate superior to that of aspirin-clopidogrel composition and high safety suitable for long -term taking.

A method for transdermal administration of a GP IIb/IIIa antagonist by iontophoresis, comprising plural electric current application steps, progressively reduced in current density. The method insures excellent pharmacologic efficacy with a low risk for side effects in the prevention and therapy of (1) angina pectoris, (2) unstable angina and (3) ischemic complications and coronary arterial reocclusion or restenosis associated with PTCA or coronary thrombolysis.

The invention discloses a metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction, comprising one or more of N-phenylalanyl-L-glutamine, sphinganine, arachidonic acid, eicosatrienoic acid, glycocholic acid, lysophosphatidylcholine (14:0), tryptophan-arginine-leucine tripeptide, lysophosphatidylcholine (18:2), and lysophosphatidylcholine (20:3). In the single use of diagnosing and distinguishing patients with acute myocardial infarction and patients with unstable angina pectoris, each ROC (receiver operating characteristic) AUC (area under the curve) is greater than 0.7, and clinical diagnostic significance is provided; in the joint use for diagnosis, AUC further increases as a joint quantity increases, a highest AUC up to 0.991 is obtained in a case of nine members jointed, and sensitivity and specificity are respectively 99.2% and 98.9% under an optimal cutoff value. The metabolic marker can accurately diagnose and distinguish unstable angina pectoris and acute myocardial infarction, with high accuracy and high sensitivity and specificity.

The invention discloses a nifedipine medicine composition and a preparation method thereof. The nifedipine medicine composition contains nifedipine, hydroxymethyl propyl cellulose and microcrystalline cellulose. The hydroxymethyl propyl cellulose is used as slow-releasing framework material; the weight ratio of the nifedipine and the hydroxymethyl propyl cellulose is 2:1-1:1; and the weight ratio of the nifedipine and the microcrystalline cellulose is 1:4-1:3; and lactose, starch, calcium hydrophosphate and glucose can be also added. The method for preparing the nifedipine medicine composition comprises the following steps of: (1) crushing and screening; (2) drying; and (3) tabletting. According to the invention, the dissolution rate of the nifedipine in the water can be increased, the coronary arteries in the normal blood supply area and the ischemic area are relaxed while the absorption rate of the nifedipine in the body is increased so that coronarospasm and is released and prevented and myocardial contraction is inhibited; myocardial oxygen consumption is reduced; the peripheral resistance is released; after load of heart is reduced; sinus node function and atrioventricular conduction of the isolated heart are slowed down; and the nifedipine medicine composition is applicable to variant angina pectoris, unstable angina pectoris and chronic stable angina pectoris.